RxDoctor Payments Data

Shekeita Perry, APRN

Nurse Practitioner · Ocala, FLNPI 1205434024

Payments from drug & device makers

$958in general payments, 2019–2025

Across 36 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$458
  • Biohaven Pharmaceutical Holding Company Ltd.$118
  • AstraZeneca$97
  • Lilly USA, LLC$52
  • Boehringer Ingelheim$47
  • Sanofi-aventis U.S. LLC$45
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$958 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$33,679
Medicare patients
121
Services billed
1,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$50,474
MounjaroTirzepatide16$26,058
FarxigaDapagliflozin Propanediol15$22,097
EliquisApixaban11$20,331
JardianceEmpagliflozin12$14,397
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,796
Atorvastatin Calcium160$1,155
Levothyroxine Sodium101$942
Oxybutynin Chloride ErOxybutynin Chloride15$846
Rosuvastatin Calcium67$803
Ezetimibe27$787
Losartan Potassium80$723
Omeprazole43$718
Amlodipine Besylate87$552
Metoprolol Succinate31$503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$50,47430 claims
Lilly USA, LLCMounjaro$52$26,05816 claims
AstraZenecaFarxiga$97$22,09715 claims
PfizerEliquis$18$20,33111 claims
Boehringer IngelheimJardiance$47$14,39712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →